Andrew G Winer1, Emily A Vertosick2, Mazyar Ghanaat3, Renato B Corradi3, Sigrid Carlsson4, Daniel D Sjoberg2, Alexander I Sankin5, John P Sfakianos6, Eugene K Cha3, Guido Dalbagni3, Jonathan A Coleman7. 1. SUNY Downstate College of Medicine and Kings County Hospital Center, Brooklyn, NY. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, NY. 3. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, NY. 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, NY; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, NY; Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 5. Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine, New York City, NY. 6. Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY. 7. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, NY. Electronic address: colemanj@mskcc.org.
Abstract
INTRODUCTION: Lymph node dissection (LND) performed during radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) remains controversial and difficult to evaluate. The aim of this study was to investigate whether removal of more lymph nodes during RNU is safe and improves oncologic outcomes. METHODS: We evaluated 422 patients who underwent RNU with concomitant LND for upper tract urothelial carcinoma between 1976 and 2015, assessing for an association between total nodes removed, recurrence-free survival, and cancer-specific survival using Cox proportional hazards models. We also investigated the relationship between nodal yield and perioperative metrics and intersurgeon variability using linear regression. RESULTS: In our cohort of 442 patients, 239 developed recurrences and 94 patients died of disease. Median follow-up among survivors was 3.7 years (interquartile range: 1.2, 7.4). The median nodal yield was 9 (interquartile range: 4, 16). Among patients with node-positive disease (pN1), we observed a significant improvement in recurrence-free survival (hazard ratio = 0.84 per 5 nodes removed, P = 0.039) and a nonsignificant improvement in cancer-specific survival with an increase in the nodal yield (hazard ratio = 0.90 per 5 nodes removed, P = 0.2). There was no evidence of an association between node yield and operative time, estimated blood loss, or 30-day complications on multivariable analysis. There was significant heterogeneity among surgeons regarding the extent of LND (P<0.0001). CONCLUSIONS: We found that a more extensive node dissection may improve oncologic outcomes in a subset of high-risk patients without significantly increasing operative time or serious complications. Additionally, we identified considerable intersurgeon heterogeneity regarding the extent of LND furthering the notion of surgeon variability as a nonstandardized factor.
INTRODUCTION: Lymph node dissection (LND) performed during radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) remains controversial and difficult to evaluate. The aim of this study was to investigate whether removal of more lymph nodes during RNU is safe and improves oncologic outcomes. METHODS: We evaluated 422 patients who underwent RNU with concomitant LND for upper tract urothelial carcinoma between 1976 and 2015, assessing for an association between total nodes removed, recurrence-free survival, and cancer-specific survival using Cox proportional hazards models. We also investigated the relationship between nodal yield and perioperative metrics and intersurgeon variability using linear regression. RESULTS: In our cohort of 442 patients, 239 developed recurrences and 94 patients died of disease. Median follow-up among survivors was 3.7 years (interquartile range: 1.2, 7.4). The median nodal yield was 9 (interquartile range: 4, 16). Among patients with node-positive disease (pN1), we observed a significant improvement in recurrence-free survival (hazard ratio = 0.84 per 5 nodes removed, P = 0.039) and a nonsignificant improvement in cancer-specific survival with an increase in the nodal yield (hazard ratio = 0.90 per 5 nodes removed, P = 0.2). There was no evidence of an association between node yield and operative time, estimated blood loss, or 30-day complications on multivariable analysis. There was significant heterogeneity among surgeons regarding the extent of LND (P<0.0001). CONCLUSIONS: We found that a more extensive node dissection may improve oncologic outcomes in a subset of high-risk patients without significantly increasing operative time or serious complications. Additionally, we identified considerable intersurgeon heterogeneity regarding the extent of LND furthering the notion of surgeon variability as a nonstandardized factor.
Authors: Maximilian Burger; Shahrokh F Shariat; Hans-Martin Fritsche; Juan Ignacio Martinez-Salamanca; Kazumasa Matsumoto; Thomas F Chromecki; Vincenzo Ficarra; Wassim Kassouf; Christian Seitz; Armin Pycha; Stefan Tritschler; Thomas J Walton; Giacomo Novara Journal: World J Urol Date: 2011-06-01 Impact factor: 4.226
Authors: M Ozsahin; A Zouhair; S Villà; G Storme; B Chauvet; D Taussky; D Gouders; G Ries; P Bontemps; P A Coucke; R O Mirimanoff Journal: Eur J Cancer Date: 1999-05 Impact factor: 9.162
Authors: Fernando P Secin; Theresa M Koppie; Juan I Martinez Salamanca; Shahid Bokhari; Ganesh V Raj; Semra Olgac; Angel Serio; Andrew Vickers; Bernard H Bochner Journal: Int J Urol Date: 2007-01 Impact factor: 3.369
Authors: Morgan Rouprêt; Marko Babjuk; Eva Compérat; Richard Zigeuner; Richard Sylvester; Max Burger; Nigel Cowan; Andreas Böhle; Bas W G Van Rhijn; Eero Kaasinen; Joan Palou; Shahrokh F Shariat Journal: Eur Urol Date: 2013-03-19 Impact factor: 20.096
Authors: Giovanni Lughezzani; Claudio Jeldres; Hendrik Isbarn; Shahrokh F Shariat; Maxine Sun; Daniel Pharand; Hugues Widmer; Philippe Arjane; Markus Graefen; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz Journal: Urology Date: 2009-10-28 Impact factor: 2.649
Authors: Arthur Peyrottes; Gianluigi Califano; Idir Ouzaïd; Paul Lainé-Caroff; Thibaut Long Depaquit; Jean-François Hermieu; Evanguelos Xylinas Journal: Front Surg Date: 2022-03-24